Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, phase Ⅱ study. This study will evaluate the efficacy and
safety of pembrolizumab in combination with disitamab vedotin in subject with HER2-expressing
metastatic Colorectal Cancer (mCRC).